Modification of L-DOPA metabolism: Benefits and problems

被引：1

作者：

Brooks, David J. ^{[1
]}

机构：

[1] Imperial Coll Sch Med, Div Neurosci, Fac Med, London, England

来源：

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2008年 / 34卷 / 01期

关键词：

D O I：

10.1016/j.ejps.2008.02.016

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：S7 / S7

页数：1

相关论文

共 50 条

[31] METABOLISM OF L-DOPA IN PIGTAIL MONKEY - EFFECT OF A-DOPA DECARBOXYLASE INHIBITOR
BRONAUGH, RL
WENGER, GR
GARVER, DL
RUTLEDGE, CO
PHARMACOLOGIST, 1974, 16 (02): : 236 - 236
[32] Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose
Heikkinen, H
Varhe, A
Laine, T
Puttonen, J
Kela, M
Kaakkola, S
Reinikainen, K
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (04) : 363 - 371
[33] L-DOPA THERAPY FOR PARKINSON SYNDROME - SITUATION AND PROBLEMS
FISCHER, PA
NERVENARZT, 1974, 45 (12): : 617 - 627
[34] RISKS OF PARKINSONISM TREATMENT WITH L-DOPA AND L-DOPA DECARBOXYLASE INHIBITOR
JORG, J
MEDIZINISCHE WELT, 1979, 30 (46): : 1740 - 1742
[35] MODIFICATION OF REHABILITATION PROCEDURES IN PARKINSONISM EFFECTED BY USE OF L-DOPA
MEYER, PR
BLONSKY, ER
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1970, A 52 (04) : 832 - &
[36] Entacapone extends the clinical benefits of L-dopa/DDCI and improves the clinical condition of PD in a range of common L-dopa dosage regimens
Beck, SC
MOVEMENT DISORDERS, 2002, 17 : S77 - S77
[37] L-DOPA AND FAVISM
BEUTLER, E
BLOOD-THE JOURNAL OF HEMATOLOGY, 1970, 36 (04): : 523 - &
[38] METHYLDOPA AND L-DOPA
不详
POSTGRADUATE MEDICINE, 1970, 47 (06) : 22 - &
[39] PRESCRIBING OF L-DOPA
DINGLE, CJ
MEDICAL JOURNAL OF AUSTRALIA, 1971, 1 (19) : 1034 - &
[40] CARDIOLOGIST AND L-DOPA
DUCLOUX, G
MOUTON, Y
WAREMBOURG, H
ANNALES DE CARDIOLOGIE ET D ANGEIOLOGIE, 1972, 21 (06): : 545 - 553

← 1 2 3 4 5 →